Details

Autor(en) / Beteiligte

• Stanley, Madison C
• Poupore, Nicolas
• Bailey‐Taylor, Melissa J
• Roley, Laurie Theriot
• Nathaniel, Thomas

Titel

Abstract Number ‐ 279: Clinical Factors of Vascular Dementia, Alzheimer’s Disease, and Mixed Vascular Dementia Stratified by Gender

Ist Teil von

• Stroke: vascular and interventional neurology, 2023-03, Vol.3 (S1)

Ort / Verlag

Phoenix: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Abstract only Introduction The different factors that contribute to gender differences among patients with vascular dementia (VaD), Alzheimer’s disease (AD), and mixed vascular dementia and Alzheimer’s disease (VDAD) are not fully understood. This study examined gender differences among patients with VaD, AD, and VDAD using demographic and pharmacologic factors. Methods Data was collected from Prisma Health‐Upstate Alzheimer registry from 2016 to 2021 for 6,039 VaD patients, 9,290 AD patients, and 412 VDAD patients. A logistic regression model was used to determine demographic and pharmacological factors that are associated with gender differences in patients with VaD, AD, and VDAD. Results In the adjusted analysis for patients with VaD, increasing age (OR = 1.023, 95% CI, 1.017‐1.029, p< 0.001) and use of aripiprazole (OR = 4.395, 95% CI, 2.880‐6.707, p< 0.001) were more associated with women, whereas use of tobacco (OR = 0.312, 95% CI, 0.278‐0.349, p< 0.001) and galantamine (OR = 0.228, 95% CI, 0.116‐0.449, p< 0.001) were more associated with men. In patients with AD, Black race (OR = 1.747, 95% CI, 1.486‐2.053, p< 0.001) and use of buspirone (OR = 1.541, 95% CI, 1.265‐1.878, p< 0.001) were more associated with women, whereas use of ETOH (OR = 0.627, 95% CI, 0.547‐0.718, p< 0.001) and memantine (OR = 0.882, 95% CI, 0.799‐0.974, p = 0.013) were more associated with men. In patients with VDAD, use of rivastigmine (OR = 3.293, 95% CI, 1.131‐9.585, p = 0.029) was more associated with women, whereas increased length of hospital stay (OR = 0.910, 95% CI, 0.828‐1.000, p = 0.049) was more associated with men. Conclusions Our study revealed that there are gender differences and similarities in the demographic and pharmacological factors of VaD, AD, and VDAD. Future studies can be conducted investigating each of these factors to improve treatment of VaD, AD, and VDADin all patients.